Upadacitinib for Refractory Alopecia Areata Unresponsive to Prior Systemic Therapies: A Retrospective Study

Published: 5 February 2025| Version 1 | DOI: 10.17632/cyygxjztsb.1
Contributor:
Wang Qin

Description

Supplemental figure I showing the efficacy of Upadacitinib; Supplemental table Idetailing baseline SALT scores, changes in SALT scores, and serum IgE levels for each patient with refractory alopecia areata following treatment with Upadacitinib; Supplementary Table II. Correlation between characteristics of alopecia areata patients treated with upadacitinib and percentage of hair regrowth at week 24w.

Files

Institutions

  • Huashan Hospital Fudan University

Categories

Hair Disorder

Licence